Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Intracerebral hemorrhage complicating intravenous tissue plasminogen-activator treatment

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Carlson, S. E.
  • Aldrich, M. S.
  • Greenberg, H. S.
  • Topol, Eric

publication date

  • 1988

journal

  • Archives of Neurology  Journal

abstract

  • Tissue plasminogen activator's thrombolytic action is relatively specific for fibrin; however, systemic bleeding can occur in patients, especially when heparin is simultaneously administered. We describe two cases of intracerebral hemorrhage from a cohort of 450 patients (0.44%) treated at one institution with tissue plasminogen activator and heparin for acute myocardial infarction. A pooled worldwide review of 5258 cases from several clinical protocols for treatment of acute myocardial infarction, using tissue plasminogen activator from one source, revealed a similar overall incidence of 0.68%. The incidence of intracerebral hemorrhage may be reduced by lowering the total dose of tissue plasminogen activator or by reducing the infusion rate and duration. The incidence of central nervous system hemorrhage with tissue plasminogen activator is within the range reported with streptokinase, but because equal coronary artery thrombolytic doses are not known, no definitive comparison is possible.

subject areas

  • Aphasia
  • Cerebral Hemorrhage
  • Female
  • Hemiplegia
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Tissue Plasminogen Activator
  • Tomography, X-Ray Computed
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0003-9942

PubMed ID

  • 3140769
scroll to property group menus

Additional Document Info

start page

  • 1070

end page

  • 1073

volume

  • 45

issue

  • 10

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support